Increase the proportion of people with sickle cell disease on Medicare who received disease-modifying therapies — BDBS‑02 Data

Status: Baseline only

  Baseline only

Most Recent Data:
12.4 percent (2016)

Target:
15.9 percent

Desired Direction:
Increase desired

Baseline:
12.4 percent of Medicare beneficiaries aged 18 to 75 years with sickle cell anemia received disease modifying therapies in accordance with the National Heart, Lung, and Blood Institute (NHLBI)'s guidelines in 2016

Disparities data are only available for some selections.

View CI in the chart by hovering over a data point.

View SE in the chart by hovering over a data point.

Confidence Interval (CI) not available Standard Error (SE) not available Confidence Interval (CI) and Standard Error (SE) are not available

Medicare beneficiaries with sickle cell anemia receiving disease modifying therapies, 2016 
(percent)
Increase desired

Population 2016
Total
12.4